文档介绍：肿瘤生物治疗最新进展肿瘤生物治疗最新进展及产业化开发及产业化开发广州蓝星生物科技开发有限公司广州蓝星生物科技开发有限公司王虹王虹●●增强机体抗肿瘤免疫; 增强机体抗肿瘤免疫; ●●诱导肿瘤细胞凋亡; 诱导肿瘤细胞凋亡; ●●抑制肿瘤血管的形成; 抑制肿瘤血管的形成; ●●提高宿主对肿瘤常规治疗的耐受力或加速损伤的恢复。提高宿主对肿瘤常规治疗的耐受力或加速损伤的恢复。肿瘤生物治疗主要策略体现在以下几方面肿瘤生物治疗主要策略体现在以下几方面: : 单克隆抗体及其偶联技术单克隆抗体及其偶联技术以单抗介导的靶向性抗肿瘤药物正成为肿瘤生物以单抗介导的靶向性抗肿瘤药物正成为肿瘤生物治疗产业化开发的热点。治疗产业化开发的热点。 1997 1997 年美国上市的利妥昔单年美国上市的利妥昔单抗( 抗( rituximab rituximab ) )为重组嵌合抗为重组嵌合抗 CD20 CD20 单克隆抗体,用于单克隆抗体,用于治疗淋巴瘤,标志着单抗已进入临床应用阶段。治疗淋巴瘤,标志着单抗已进入临床应用阶段。抗体药物销售趋势图抗体药物销售趋势图 September 1998 September 1998 Genentech Genentech Herceptin Herceptin Metastatic Metastatic breast cancer breast cancer CDR-grafted CDR-grafted May 2000 May 2000 American Home American Home Products Products Mylotarg Mylotarg Acute myeloid leukemia Acute myeloid leukemia CDR-grafted CDR-grafted May 1998 May 1998 Novartis Novartis Simulect an rejection rejection prophylaxis prophylaxis Chimeric Chimeric August 1998 August 1998 ohnson ohnson & Johnson & Johnson Remicade Remicade Rheumatoid Rheumatoid arthritis, arthritis, Crohn Crohn 's disease 's disease Chimeric Chimeric December 1997 December 1997 Roche Roche Zenapax an rejection an rejection prophylaxis CDR-grafted CDR-grafted June 1998 June 1998 Medimmune Medimmune Synagis Synagis Respiratory Respiratory syncytial syncytial virus virus CDR-grafted CDR-grafted September 1998 September 1998 Genentech Genentech Herceptin Herceptin Metastatic Metastatic breast cancer breast cancer CDR-grafted CDR-grafted November 1997 November 1997 Genentech Genentech Rituxan Rituxan Non-Hodgkin's Non-Hodgkin's lymphoma lymphoma Chimeric Chimeric Approved Approved Marketer Marketer Product Product Type Type Monoclonal Antibodies on the Market Monoclonal Antibodies on the Market March 2002 March 2002 IDEC Pharmaceuticals IDEC Pharmaceuticals and and Schering Schering AG AG Zevalin Zevalin Non-Hodgkin's Lymphoma Non-Hodgkin's Lymphoma Murine Murine Radiolabeled Radiolabeled December 2002 December 2002 Abbott Laboratories Abbott Laboratories Humira